Abstract
Background While neurological manifestations are core features of Fabry disease (FD), quantitative neuroimaging biomarkers allowing to measure brain involvement are lacking. We used deep learning and the brain-age paradigm to assess whether FD patients’ brains appear older than normal and to validate brain-predicted age difference (brain-PAD) as a possible disease severity biomarker.
Methods MRI scans of FD patients and healthy controls (HC) from a single Institution were retrospectively studied. The Fabry stabilization index (FASTEX) was recorded as a measure of disease severity. Using minimally preprocessed 3D T1-weighted brain scans of healthy subjects from 8 publicly available sources (N=2160; mean age=33y[range 4-86]), we trained a model predicting chronological age based on a DenseNet architecture and used it to generate brain-age predictions in the internal cohort. Within a linear modeling framework, brain-PAD was tested for age/sex-adjusted associations with diagnostic group (FD vs HC), FASTEX score, and both global and voxel-level neuroimaging measures.
Results We studied 52 FD patients (40.6±12.6y; 28F) and 58 HC (38.4±13.4y; 28F). The brain-age model achieved accurate out-of-sample performance (mean absolute error=4.01y, R2=0.90). FD patients had significantly higher brain-PAD than HC (estimated marginal means: 3.1vs-0.1, p=0.01). Brain-PAD was associated with FASTEX score (B=0.10, p=0.02), brain parenchymal fraction (B=-153.50, p=0.001), white matter hyperintensities load (B=0.85, p=0.01), and tissue volume reduction throughout the brain.
Conclusions We demonstrated that FD patients’ brains appear older than normal. Brain-PAD correlates with FD-related multi-organ damage and is influenced by both global brain volume and white matter hyperintensities, offering a comprehensive biomarker of (neurological) disease severity.
Summary Statement Using deep learning and the brain-age paradigm, we found that Fabry disease is associated with older-appearing brains. The gap between brain-predicted and chronological age correlates with multi-organ disease severity, offering a novel quantitative neuroimaging biomarker.
Key Points
Patients with Fabry disease show significantly higher brain-predicted age difference values compared to healthy controls (estimated marginal means: 3.1 vs -0.1, p=0.01).
Brain-predicted age difference correlates with multi-organ disease severity and is associated with brain parenchymal fraction, white matter hyperintensities load, and tissue volume throughout the brain.
Brain-predicted age difference might represent a sensitive quantitative biomarker of brain involvement in Fabry disease, with potentially relevant implications for patient stratification and treatment response monitoring.
Competing Interest Statement
Frederik Barkhof: Steering committee and iDMC member for Biogen, Merck, Roche, EISAI. Consultant for Roche, Biogen, Merck, IXICO, Jansen, Combinostics. Research agreements with Novartis, Merck, Biogen, GE, Roche. Co-founder and share-holder of Queen Square Analytics LTD. Maria Petracca discloses travel/meeting expenses from Novartis, Janssen, Roche and Merck, speaking honoraria from HEALTH&LIFE S.r.l. and AIM Education S.r.l., honoraria for consulting services from Biogen and research grants from Baroni Foundation. Sirio Cocozza serves on scientific advisory board for Amicus Therapeurics, has received speaker honoraria from Sanofi and research grants from Fondazione Italiana Sclerosi Multipla and Telethon. Giuseppe Pontillo was supported by the MAGNIMS/ECTRIMS (2020) and ESNR (2021) research fellowship programs. The remaining authors have nothing to disclose.
Funding Statement
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee of University of Naples "Federico II" gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Main Institution: University “Federico II”, Via Pansini 5, 80131 - Naples - Italy
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.